MAM
PBYI icon

Martingale Asset Management’s Puma Biotechnology PBYI Stock Holding History

Martingale Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Buy
+25,364
New +$186K ﹤0.01% 818
2015
Q1 		– Sell
-1,127
Closed -$214K – 892
2014
Q4 		$214K Buy
+1,127
New +$250K 0.01% 815

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Martingale Asset Management's PBYI Position: Q2 2026 in Review

Martingale Asset Management opened a new position in Puma Biotechnology (PBYI) in Q2 2026: 25,364 shares worth $206K. The stake represents ﹤0.01% of the portfolio and ranks #818 among its holdings. This is a return to the name: Martingale Asset Management previously reported a position in PBYI as recently as Q4 2014.

Martingale Asset Management first reported a position in PBYI in Q4 2014 and has held it in 2 quarters since. The position peaked at $214K in Q4 2014. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Martingale Asset Management held 25,364 shares of Puma Biotechnology worth $206K as of Q2 2026.
  • Puma Biotechnology was a new Martingale Asset Management position in Q2 2026.
  • Puma Biotechnology made up ﹤0.01% of Martingale Asset Management's portfolio in Q2 2026, its #818 holding.
  • Martingale Asset Management first reported a position in Puma Biotechnology in Q4 2014 and has held it in 2 quarters since.
  • Martingale Asset Management's Puma Biotechnology position peaked at $214K in Q4 2014.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.